Supernus Pharmaceuticals (NASDAQ:SUPN) Given Neutral Rating at Cantor Fitzgerald

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “neutral” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $36.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 9.72% from the company’s current price.

Supernus Pharmaceuticals Stock Up 0.4 %

Supernus Pharmaceuticals stock opened at $32.81 on Wednesday. The company has a market capitalization of $1.81 billion, a P/E ratio of 30.66 and a beta of 0.90. The firm has a 50 day moving average price of $37.34 and a 200-day moving average price of $35.39. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock worth $440,263 over the last ninety days. 9.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Raiffeisen Bank International AG purchased a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $42,000. Smartleaf Asset Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $52,000. Finally, Headlands Technologies LLC grew its stake in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,015 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.